Progesterone (NSC 9704)

Catalog No.S1705 Synonyms: NSC 64377, Pregn-4-ene-3,20-dione

For research use only.

Progesterone (NSC 9704, NSC 64377, Pregn-4-ene-3,20-dione) is an endogenous steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species. A potent agonist of the nuclear progesterone receptor (nPR) with Kd of 1 nM; An agonist of the membrane progesterone receptors(mPRs); An antagonist of the σ1 receptor.

Progesterone (NSC 9704) Chemical Structure

CAS No. 57-83-0

Selleck's Progesterone (NSC 9704) has been cited by 9 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Other Estrogen/progestogen Receptor Products

Biological Activity

Description Progesterone (NSC 9704, NSC 64377, Pregn-4-ene-3,20-dione) is an endogenous steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species. A potent agonist of the nuclear progesterone receptor (nPR) with Kd of 1 nM; An agonist of the membrane progesterone receptors(mPRs); An antagonist of the σ1 receptor.
Targets
progestogen Receptor [1]
In vitro

Progesterone has biphasic effects on proliferation of breast cancer cells; it stimulates growth in the first cell cycle, then arrests cells at G1/S of the second cycle accompanied by up-regulation of the cyclin-dependent kinase inhibitor, p21. Progesterone-mediated transcription is further prevented by overexpression of E1A, suggesting that CBP/p300 is required. [1] Progesterone drives a series of events where luminal cells probably provide Wnt4 and RANKL signals to basal cells which in turn respond by upregulating their cognate receptors, transcriptional targets and cell cycle markers. [2] Progesterone treatment increases the sensitivity of cortical synaptoneurosomes to GABA (i.e., decreased the EC50) and increases the maximal efficacy with which GABA stimulated Cl- transport (i.e., increased the Emax). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human T47D cells M1PBOGZ2dmO2aX;uJIF{e2G7 MV6yNEBp Mnn1RYN1cX[jdHnvckBw\iCycn;n[ZN1\XKxbnWgdoVk\XC2b4KgbY4hcHWvYX6gWFQ4TCClZXzsd{Bi\nSncjCyNEBpenNiYomgVHJGNXSjZ3fl[EBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5zIH7N Mnq2NVk5PjNyOEO=
CV-1 cells MlS4SpVv[3Srb36gZZN{[Xl? NGnGXoZG\m[nY4TpeoUh[2:wY3XueJJifGmxbjDmc5IhcGGuZj3tZZhqdWGuIHHjeIl3[XSrb36gc4YhcHWvYX6gdJJw\2W|dHXyc45mKHKnY3XweI9zKGW6cILld5Nm\CCrbjDDWk0yKGOnbHzzMEBGSzVyPUGuOUBvVQ>? NEnyR4Y6PjZ5OU[4
HEK293 cells NV3ycWNVTnWwY4Tpc44h[XO|YYm= MojORYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVmdTKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPUKgcm0> M4PHcVI2OzB3Nki4
SF-12 cells NHr2RXdHfW6ldHnvckBie3OjeR?= M1jqWGRqe3CuYXPlcYVvfCCxZjDETHQh\nKxbTDoeY1idiCjbnTyc4dmdiC{ZXPldJRweiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhW0ZvMUKgZ4VtdHNuIFvpQVkvPSCwTR?= M2K0ZVEzQTV2ME[y
CHO cells NXTWS25UTnWwY4Tpc44h[XO|YYm= MkjCRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDUS3I2KGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZpkhdHWlaX\ldoF{\SCjc4PhfUwhTUN3ME2yMlc4KM7:TR?= MYSxPFMxPzJ7NB?=
human K562/R7 cells NWPmbGVSTnWwY4Tpc44h[XO|YYm= M1fNTFEh|ryP NV\IXndLPzJiaB?= NXXYd|VmWG:2ZX70bYF1cW:wIH;mJIRwgG:{dXLpZ4lvNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHHnZYlve3RiZH;4c5J2[mmlaX6tdoV{cXO2YX70JIh2dWGwIFu1OlIwWjdiY3XscJMh[XO|ZYPz[YQh[XNiZH;4c5J2[mmlaX6gTWM2OCCjdDCxJJVOKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NVAvPiEQvF2= NHvCSHozPTZ|NEC0NS=>
A2780 cells M3TxfGZ2dmO2aX;uJIF{e2G7 MWHJcohq[mm2aX;uJI9nKFBvZ4CgbY4hcHWvYX6gZYRzcWGveXPpck1z\XOrc4ThcpQhSTJ5OECgZ4VtdHNiYomgTI9m[2i|dDCzN|M1OiCjc4PhfUwhUUN3ME20O{45PjNizszN MWCxPFY4QDR7NR?=
HeLa cells MUPDfZRwfG:6aXPpeJkh[XO|YYm= NH3xfWxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhTE6DIILldIxq[2G2aX;uJIJ6KGmvYXfpcoch[W6jbInzbZM> MYixPFA3PjB3NR?=
In vivo Progesterone blocks the beneficial effect of estrogen on Abeta accumulation but not on behavioral performance in female 3xTg-AD mice. Progesterone significantly reduces tau hyperphosphorylation when administered both alone and in combination with estrogen. [4] Progesterone-treated rats are less impaired on a Morris water maze spatial navigation task than rats treated with the oil vehicle. Progesterone-treated rats also show less neuronal degeneration 21 days after injury in the medial dorsal thalamic nucleus, a structure that has reciprocal connections with the contused area. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 314.46
Formula

C21H30O2

CAS No. 57-83-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04922424 Not yet recruiting Drug: Atorvastatin|Other: placebo Hypertension|Hyperlipidemias Yale University September 30 2022 Phase 1
NCT04814940 Not yet recruiting Other: MENOPUR Cohort Infertility Female Ferring Pharmaceuticals September 1 2022 --
NCT04989972 Withdrawn Drug: PSIL428|Dietary Supplement: Oyster mushroom Anxiety and Depression Wake Network Inc.|Professor Roger Gibson Section of Psychiatry Faculty of Medical Sciences UWI September 15 2022 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Progesterone (NSC 9704) | Progesterone (NSC 9704) ic50 | Progesterone (NSC 9704) price | Progesterone (NSC 9704) cost | Progesterone (NSC 9704) solubility dmso | Progesterone (NSC 9704) purchase | Progesterone (NSC 9704) manufacturer | Progesterone (NSC 9704) research buy | Progesterone (NSC 9704) order | Progesterone (NSC 9704) mouse | Progesterone (NSC 9704) chemical structure | Progesterone (NSC 9704) mw | Progesterone (NSC 9704) molecular weight | Progesterone (NSC 9704) datasheet | Progesterone (NSC 9704) supplier | Progesterone (NSC 9704) in vitro | Progesterone (NSC 9704) cell line | Progesterone (NSC 9704) concentration | Progesterone (NSC 9704) nmr